Health Care & Life Sciences » Biotechnology | Blueprint Medicines Corp.

Blueprint Medicines Corp. | Ownership

Companies that own Blueprint Medicines Corp.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
5,291,252
12.06%
1,069
0.04%
06/30/2018
The Vanguard Group, Inc.
3,537,679
8.06%
237,743
0.01%
06/30/2018
T. Rowe Price Associates, Inc.
3,122,318
7.11%
-346,249
0.03%
06/30/2018
BlackRock Fund Advisors
2,968,695
6.76%
44,510
0.01%
06/30/2018
Wellington Management Co. LLP
2,700,399
6.15%
24,249
0.04%
06/30/2018
SSgA Funds Management, Inc.
1,849,283
4.21%
293,760
0.01%
06/30/2018
OppenheimerFunds, Inc.
1,677,731
3.82%
64,095
0.08%
06/30/2018
Hillhouse Capital Management Ltd. (Hong Kong)
1,430,949
3.26%
62,500
1.23%
06/30/2018
FIAM LLC
1,284,348
2.93%
87,467
0.19%
06/30/2018
TimesSquare Capital Management LLC
1,070,940
2.44%
234,565
0.47%
06/30/2018

About Blueprint Medicines

View Profile
Address
45 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.blueprintmedicines.com
Updated 07/08/2019
Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.